1. Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer
- Author
-
Max Liu, Xiaoying S. Zhong, Srikruthi S. Krishnachaitanya, Rongliwen Ou, Roderick H. Dashwood, Don W. Powell, and Qingjie Li
- Subjects
Inflammatory bowel disease ,Colorectal cancer ,Ulcerative colitis ,Tarceva ,Epidermal growth factor receptor ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Colitis-associated cancer (CAC) in inflammatory bowel diseases exhibits more aggressive behavior than sporadic colorectal cancer; however, the molecular mechanisms remain unclear. No definitive preventative agent against CAC is currently established in the clinical setting. We investigated the molecular mechanisms of CAC in the azoxymethane/dextran sulfate sodium (AOM/DSS) mouse model and assessed the antitumor efficacy of erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR). Erlotinib premixed with AIN-93 G diet at 70 or 140 parts per million (ppm) inhibited tumor multiplicity significantly by 96%, with ∼60% of the treated mice exhibiting zero polyps at 12 weeks. Bulk RNA-sequencing revealed more than a thousand significant gene alterations in the colons of AOM/DSS-treated mice, with KEGG enrichment analysis highlighting 46 signaling pathways in CAC development. Erlotinib altered several signaling pathways and rescued 40 key genes dysregulated in CAC, including those involved in the Hippo and Wnt signaling. These findings suggest that the clinically-used antitumor agent erlotinib might be repurposed for suppression of CAC, and that further studies are warranted on the crosstalk between dysregulated Wnt and EGFR signaling in the corresponding patient population.
- Published
- 2024
- Full Text
- View/download PDF